DTaP and Tdap Market Outlook on product overview Application and region & # 39; s 2023 – Press release



This press release was originally distributed by SBWire

Maharashtra, India – (SBWIRE) – 09/05/2018 – DTaP and Tdap Market
Overview

Pertussis vaccine is used for whooping cough. This vaccine is only available in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teenagers and pregnant women. Diphtheria, tetanus and pertussis (DTaP) vaccines are given to children under seven years of age, while tetanus, diphtheria and pertussis (Tdap) vaccines are given to older children and adults. Vaccination for children is one of the safest and most cost-effective ways for a pertussis-free environment.

Browse more detailed information from the report at https://www.reportsmonitor.com/request_sample/95204

The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend that all children should be routinely vaccinated for whooping cough. According to the WHO, in 2015 about 86% of babies worldwide received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine to protect against infectious diseases. In 2015, the purchase of the DTWP vaccine via UNICEF amounted to 5.8 million doses for 18 countries and territories, of which four countries such as Egypt, Morocco, Uzbekistan and Zimbabwe accounted for more than 80% of total UNICEF procurement.

Major players in the DTaP and Tdap markets are: Sanofi Pasteur, GlaxoSmithKline, Protein Sciences Corporation, Novartis AG, Seqirus, Merck Sharp & Dohme Corp., Astellas Pharma US, Inc., Pfizer Inc., Johnson & Johnson, Lanzhou Institute of Biological Products Co., Ltd, AstraZeneca, Emergent BioSolutions Inc.

Major regions play a vital role in the DTaP and Tdap markets: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia Pacific (China, Japan) , Korea, India and Southeast Asia)), South America (Brazil, Argentina, Colombia, etc.), Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Check the discount for this report at https://www.reportsmonitor.com/check_discount/95204

Research framework

Factors such as a high birth rate, an increase in the number of geriatric patients, government initiatives, the growth in the acceptance of whooping cough vaccination and the government salary and reimbursement scenario are expected to stimulate the whooping cough vaccine market worldwide. According to the World Health Organization in 2015, 126 countries had achieved coverage of at least 90% of the vaccine against diphtheria-tetanus pertussis. On the other hand, factors such as vaccine damage and adverse events are expected to impede the growth of the pertussis vaccine market worldwide. In the US in 2015, 7 claims were submitted in the federal vaccination certification program (VICP) for injuries and deaths after vaccination against whooping cough, including three deaths and four serious injuries.

The whooping cough vaccine market is segmented by product type, vaccine type, age group, end user and geography. As far as the product type is concerned, the vaccine market for whooping cough is classified in the DTaP vaccine and the Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel and Quaracel. T

The Tdap vaccine segment includes products such as Boostrix and Adacel. As far as the vaccine type is concerned, the market for whooping cough vaccines is classified in the whole cell vaccine and the acellular vaccine. The acellular vaccine segment is strongly used because of fewer side effects. The acellular vaccine is approximately 71% -85% effective, while the whole cell vaccine is about 78% effective. As far as the age group is concerned, the vaccine market for whooping cough is classified in adults and children. As far as the end user is concerned, the market is divided into hospitals, clinics and vaccination centers. Geographically, the pertussis vaccine market is classified in North America, Latin America, Europe, Asia Pacific and Middle East and Africa.

North America dominates the pertussis vaccine market due to the growth in the number of geriatric patients and the increase in the number of pertussis deaths in the US, which stimulate the whooping cough vaccination market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the US. The North American market is followed by the markets in Europe and Asia / Pacific. From Asia to the Pacific, it is expected that it will grow at a faster pace as a result of the rapid population growth, the increase in adoption for vaccination and the growth in the prevalence of infectious diseases. It is expected that these factors will feed the whooping cough vaccine market.

In the Asia-Pacific region, Thailand accounts for 99% of the vaccine coverage for whooping cough, followed by Japan and China with 98% and 97% respectively. Developing countries such as Brazil, South Africa and Mexico are estimated to create good opportunities for the growth of whooping cough vaccination due to an increase in the number of health insurance policies for the government and private health care, increased healthcare expenditures and increased awareness of people.

Scope of the report:

Global DTaP and Tdap market: Type Outlook: DTaP, Td, Tdap.

Global DTaP and Tdap market: Application Outlook: Adult, Pediatric.

Reasons to buy:

– Visualize the composition of the DTaP and TdapMarket, in terms of the different applications of the (market name), and underline the main sources and players of the sector.

– Investigate the product pipeline and research per stage of the disease, molecular target, with a grainy degradation of the main symptoms.

– Understand the growth with regard to the (market name) and market turnover for the global market and over the main players and market segments.

– Study the market in terms of generic and premium product sales.

– Determine commercial opportunities in the sales scenario of DTaP and TdapMarket by analyzing trends in permits and joint development deals.

Read detailed report @ https://www.reportsmonitor.com/report/95204/DTaP-and-Tdap-Vaccines-Market

Thank you for reading this article; you can also get a separate chapter-by-section or regional report version, such as Asia, the United States and Europe.

For more information on this press release, visit: http://www.sbwire.com/press-releases/dtap-and-tdap-market-outlook-by-product-overview-application-and-regions-2023-1041344.htm


Source link

Leave a Reply